Free Trial
Robert Driscoll

Robert Driscoll Analyst Performance

Senior Vice President, Equity Research at Wedbush

Robert Driscoll is a stock analyst at Wedbush, covering 15 publicly traded companies across a range of sectors. Over the past year, Robert Driscoll has issued 12 stock ratings, including buy and hold recommendations. While full access to Robert Driscoll's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Robert Driscoll's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
20 Last 7 Years
Buy Recommendations
70.00% 14 Buy Ratings
Companies Covered
15 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy70.0%14 ratings
Hold25.0%5 ratings
Sell5.0%1 ratings

Out of 20 total stock ratings issued by Robert Driscoll at Wedbush, the majority (70.0%) have been Buy recommendations, followed by 25.0% Hold and 5.0% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
15 companies

Robert Driscoll, an analyst at Wedbush, currently covers 15 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
15 companies
100.0%

Robert Driscoll of Wedbush specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
10 companies
66.7%
BIOTECHNOLOGY
2 companies
13.3%
PHARMACEUTICAL PREPARATIONS
2 companies
13.3%
MED - DRUGS
1 company
6.7%

About Robert Driscoll

Robert Driscoll, Ph.D., has over a decade in research and analytics in the life sciences sector – specifically in the area of oncology and more recently in the areas of infectious disease. He is a molecular biologist who received his Ph.D. from the University of Cambridge, and spent six additional years working in the lab at Stanford. He is particularly interested in the development and causes of cancer, as well as the expanding world of immuno-oncology. Since joining Wedbush in 2014, Robert has been covering a number of cutting-edge companies that include Arvinas (ARVN), Kura Oncology (KURA), Arcus Biosciences (RCUS), and IGM Biosciences (IGMS). Robert received his Bachelor’s degree in Biochemistry from the University of Leeds, and his Ph.D. in Cellular and Molecular Biology from the University of Cambridge. He also completed a postdoctoral fellowship at Stanford University.
Follow on LinkedIn

Robert Driscoll's Ratings History at Wedbush

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Replimune Group, Inc. stock logo
REPL
Replimune Group
7/22/2025Reiterated Rating$3.14$4.00Neutral
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
7/14/2025Initiated Coverage$12.96$27.00Outperform
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
6/20/2025Reiterated Rating$6.06$36.00Outperform
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
5/15/2025Reiterated Rating$1.18$4.00Neutral
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
5/9/2025Lower Price Target$0.82$6.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4/28/2025Reiterated Rating$41.02$67.00Outperform
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
3/28/2025Reiterated Rating$1.70$4.00Neutral
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
3/20/2025Reiterated Rating$7.06$17.00Outperform
Arvinas, Inc. stock logo
ARVN
Arvinas
3/12/2025Downgrade$8.30$12.00Neutral
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
3/12/2025Reiterated Rating$1.30$8.00Outperform
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
2/26/2025Reiterated Rating$10.25$32.00Outperform
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2/6/2025Boost Price Target$8.13$36.00Outperform